Tag: t cell specific surface glycoprotein cd28 market overview

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

T Cell Specific Surface Glycoprotein CD28 Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

The t cell specific surface glycoprotein cd28 market size has demonstrated significant expansion in recent years. It is projected to increase from $1.62 billion in 2025 to $1.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.0%. This historical growth can be attributed to factors such as the early identification of cd28 as a t-cell co-stimulatory receptor, growing immunology research, the increasing prevalence of autoimmune diseases, rising cancer research initiatives, and the limited availability of monoclonal antibody therapies.

The t cell specific surface glycoprotein cd28 market size is anticipated to undergo substantial growth in the upcoming years. It is projected to expand to $2.58 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 9.7%. This forecasted growth can be attributed to the advancement of lulizumab pegol and novel cd28 inhibitors, the increase in preclinical and clinical trials, the integration of cd28-targeted therapies into autoimmune and cancer treatments, a rise in biopharmaceutical research investments, and improvements in immunomodulation and monoclonal antibody engineering. Key trends expected during the forecast period include the broader adoption of flow cytometry and ELISA technologies, an increase in immunology and cancer research applications, the continued development of new cd28 inhibitors and biobetters, the expansion of research into stem cells and autoimmune diseases, and the incorporation of lulizumab pegol in preclinical and clinical studies.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=48780622&type=smp&name=T%20Cell%20Specific%20Surface%20Glycoprotein%20CD28%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

T Cell Specific Surface Glycoprotein CD28 Market Industry Drivers: What’s Behind The Revenue Growth?

The T cell-specific surface glycoprotein CD28 market is anticipated to expand due to the increasing focus on personalized medicine. This medical strategy involves customizing treatments for individual patients, considering their genetic, environmental, and lifestyle elements to enhance results and care. The rising need for personalized medicine is fueled by progress in genomic technologies, which allow for accurate detection of genetic variations and customized therapies for individuals. T cell-specific surface glycoprotein CD28 aids personalized medicine by facilitating targeted immune modulation, thereby making treatments more accurate and efficient. It boosts treatment efficacy through encouraging ideal T cell activation, consequently bettering patient-specific immune responses. As an illustration, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that the U.S. Food and Drug Administration (FDA) cleared 26 new personalized medicines in 2023, a rise from 12 approved in 2022. Consequently, the increasing prioritization of personalized medicine is propelling the T cell-specific surface glycoprotein CD28 market’s expansion.

T Cell Specific Surface Glycoprotein CD28 Market Segments: Where Is Growth Concentrated?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented –

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

#T Cell Specific Surface Glycoprotein CD28 Market Growth Trends: What’s Shaping The Future Outlook?

Key companies operating within the T cell-specific surface glycoprotein CD28 market are concentrating on developing innovative products, such as combination immunotherapies, to improve T cell activation, anti-tumor efficacy, and patient treatment outcomes. Combination immunotherapies represent treatments that integrate multiple immune-based approaches to enhance the body’s capability to combat disease. For instance, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, unveiled preclinical data concerning RNDO 564, a novel CD28 Nectin 4 costimulatory bispecific antibody intended for advanced bladder cancer. This antibody is engineered to selectively activate CD28 on T cells when it binds to Nectin-4-expressing tumor cells, thereby augmenting T-cell-mediated tumor killing while minimizing off-target toxicity. The presented data demonstrated powerful anti-tumor activity in preclinical models, supporting its continued development as a potential therapy for patients diagnosed with metastatic urothelial carcinoma.

T Cell Specific Surface Glycoprotein CD28 Market Key Participants And Competitive Landscape

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

View The Full T Cell Specific Surface Glycoprotein CD28 Market Report:

https://thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

T Cell Specific Surface Glycoprotein CD28 Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

T Cell Specific Surface Glycoprotein CD28 Market Forecast Highlighting Growth From $1.78 Billion To $2.57 Billion

The market size for T cell-specific surface glycoprotein CD28 has experienced notable expansion in recent years. From $1.62 billion in 2025, it is forecasted to reach $1.78 billion by 2026, achieving a compound annual growth rate (CAGR) of 10.0%. This historic growth has been driven by several factors, including the early recognition of CD28 as a co-stimulatory receptor on T cells, heightened focus on immunology research, a growing incidence of autoimmune diseases, increased investment in cancer research efforts, and constraints in the supply of monoclonal antibody therapies.

The market for the T cell-specific surface glycoprotein CD28 is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $2.58 billion, reflecting a compound annual growth rate (CAGR) of 9.7%. This forecasted growth is driven by factors such as the development of lulizumab pegol and novel CD28 inhibitors, the broadening of preclinical and clinical trial activities, the incorporation of CD28-targeted therapies into treatments for autoimmune diseases and cancer, heightened investment in biopharmaceutical research, and progress in immunomodulation and monoclonal antibody engineering. Key trends shaping the forecast period include the growing use of flow cytometry and ELISA technologies, an uptick in immunology and cancer research applications, the emergence of new CD28 inhibitors and biobetters, the expansion of research into stem cells and autoimmune disorders, and the inclusion of lulizumab pegol in preclinical and clinical investigations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

T Cell Specific Surface Glycoprotein CD28 Market Opportunity Drivers: What Is Creating New Revenue Potential?

The rising focus on personalized medicine is anticipated to fuel the expansion of the T cell-specific surface glycoprotein CD28 market in the coming period. Defined as a healthcare strategy that customizes treatments for individuals by taking into account their genetic makeup, environmental exposures, and lifestyle habits, personalized medicine aims to enhance outcomes and improve the quality of care. Its adoption is accelerating, driven by progress in genomic technologies that allow for accurate detection of genetic differences and the development of customized therapies. By facilitating targeted immune modulation, the T cell-specific surface glycoprotein CD28 contributes to personalized medicine, increasing the precision and effectiveness of treatments. This approach improves therapeutic results through the promotion of optimal T cell activation, thereby boosting immune responses specific to each patient. As an example, the Personalized Medicine Coalition (PMC), a nonprofit organization based in the United States, reported in February 2024 that the U.S. Food and Drug Administration (FDA) gave approval to 26 new personalized medicines during 2023, a notable rise from the 12 approvals recorded in 2022. Consequently, the growing emphasis on personalized medicine is driving the growth of the T cell-specific surface glycoprotein CD28 market.

T Cell Specific Surface Glycoprotein CD28 Market Segment Landscape: Which Areas Lead Market Development?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented –

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

T Cell Specific Surface Glycoprotein CD28 Market Innovation Trends Driving Future Development

Key players in the T cell-specific surface glycoprotein CD28 market are prioritizing the creation of advanced solutions, particularly combination immunotherapies, with the goal of improving T cell activation, anticancer effectiveness, and overall patient outcomes. These combination immunotherapies employ several immune-focused strategies together to strengthen the body’s ability to combat diseases. A notable example occurred in February 2025, when Rondo Therapeutics Inc., a biopharmaceutical firm based in the US, shared preclinical findings for RNDO 564, a pioneering CD28 Nectin-4 costimulatory bispecific antibody designed for advanced bladder cancer. This agent is specifically formulated to trigger CD28 on T cells once it attaches to Nectin-4 on tumor cells, thereby boosting T-cell-mediated destruction of cancer cells and reducing unintended toxic effects. The results showed strong antitumor activity in preclinical models, paving the way for its continued development as a possible treatment for individuals with metastatic urothelial carcinoma.

T Cell Specific Surface Glycoprotein CD28 Market Industry Leaders And Market Competition

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Access The Complete T Cell Specific Surface Glycoprotein CD28 Market Report:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

T Cell Specific Surface Glycoprotein CD28 Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The T Cell Specific Surface Glycoprotein CD28 Market Over The Forecast Period?

The t cell specific surface glycoprotein cd28 market size has seen substantial growth in recent years. It is anticipated to increase from $1.62 billion in 2025 to $1.78 billion in 2026, at a compound annual growth rate (CAGR) of 10.0%. The expansion observed in the past can be attributed to the early recognition of cd28 as a t-cell co-stimulatory receptor, a rise in immunology research, the increasing occurrence of autoimmune diseases, growing initiatives in cancer research, and the constrained access to monoclonal antibody therapies.

The t cell specific surface glycoprotein cd28 market size is anticipated to experience robust growth over the next few years. It is forecast to reach $2.58 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.7%. The expansion during the projected period can be attributed to the development of lulizumab pegol and innovative cd28 inhibitors, the increasing number of preclinical and clinical trials, the integration of cd28-targeted treatments into autoimmune and cancer therapies, rising investments in biopharmaceutical research, and advancements in immunomodulation and monoclonal antibody engineering. Key trends for the forecast period include the growing adoption of flow cytometry and ELISA technologies, an increase in immunology and cancer research applications, the progressing development of novel cd28 inhibitors and biobetters, the expansion of stem cell and autoimmune disease research, and the incorporation of lulizumab pegol in preclinical and clinical studies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

Which Strategic Drivers Are Supporting The T Cell Specific Surface Glycoprotein CD28 Market Development?

The increasing focus on personalized medicine is anticipated to fuel the expansion of the T cell-specific surface glycoprotein CD28 market moving forward. Personalized medicine is a medical approach that tailors treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for this approach is rising due to advancements in genomic technologies, which facilitate the precise identification of genetic variations and customized treatments for individuals. T cell-specific surface glycoprotein CD28 supports personalized medicine by enabling targeted immune modulation, making therapies more precise and effective. It enhances treatment outcomes by promoting optimal T cell activation, thereby improving patient-specific immune responses. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, an increase from 12 approved in 2022. Thus, the growing emphasis on personalized medicine is driving the growth of the T cell-specific surface glycoprotein CD28 market.

How Is The T Cell Specific Surface Glycoprotein CD28 Market Structured Across Different Market Segments?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented –

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

What Trends Are Impacting The T Cell Specific Surface Glycoprotein CD28 Market?

Key players within the T cell-specific surface glycoprotein CD28 market are prioritizing the creation of innovative offerings, particularly combination immunotherapies, aimed at elevating T cell activation, enhancing anti-tumor efficacy, and improving patient outcomes. Such immunotherapies involve therapeutic strategies that merge several immune-centric methods to strengthen the body’s natural defense against illness. An illustrative example occurred in February 2025, when Rondo Therapeutics Inc., a biopharmaceutical firm based in the US, unveiled preclinical findings concerning RNDO 564, an innovative CD28 Nectin 4 costimulatory bispecific antibody designed for advanced bladder cancer. This antibody is engineered to specifically activate CD28 on T cells when it binds to tumor cells that express Nectin-4, thereby boosting T-cell-mediated tumor elimination while concurrently reducing toxicity to healthy cells. The gathered data exhibited strong anti-tumor activity in preclinical models, lending support for its continued development as a prospective treatment for individuals suffering from metastatic urothelial carcinoma.

Which Companies Are Engaged In The T Cell Specific Surface Glycoprotein CD28 Market Environment?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Access The Complete T Cell Specific Surface Glycoprotein CD28 Market Report:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

Which Regional Market Leads The T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access T Cell Specific Surface Glycoprotein CD28 Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2026, By The Business Research Company

Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/monitor-global-market-report

Display Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/display-monitor-global-market-report

Holter Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The T Cell Specific Surface Glycoprotein CD28 Market Over The 2026–2030 Period?

The market size for t cell specific surface glycoprotein cd28 has experienced robust growth in recent years. It is anticipated to expand from $1.62 billion in 2025 to $1.78 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.0%. The historical period’s growth can be primarily attributed to the early identification of cd28 as a t-cell co-stimulatory receptor, expanding immunology research, a rising prevalence of autoimmune diseases, increasing cancer research initiatives, and the limited availability of monoclonal antibody therapies.

The t cell specific surface glycoprotein cd28 market is poised for robust expansion over the coming years, with projections indicating it will attain a size of $2.58 billion by 2030, advancing at a compound annual growth rate (CAGR) of 9.7%. This anticipated growth during the forecast period is primarily attributable to several factors, including the ongoing development of lulizumab pegol and novel cd28 inhibitors, the broadening scope of preclinical and clinical trials, the integration of cd28-targeted therapies into both autoimmune and cancer treatment protocols, a surge in investment within biopharmaceutical research, and advancements in immunomodulation and monoclonal antibody engineering. Noteworthy trends anticipated in this period encompass the increasing adoption of flow cytometry and ELISA technologies, an uptick in applications across immunology and cancer research, the escalating development of innovative cd28 inhibitors and biobetters, an expansion in stem cell and autoimmune disease research efforts, and the incorporation of lulizumab pegol into preclinical and clinical studies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

Which Economic Or Industry Drivers Are Impacting The T Cell Specific Surface Glycoprotein CD28 Market?

The future expansion of the T cell-specific surface glycoprotein CD28 market is anticipated, driven by the increasing focus on personalized medicine. This medical strategy customizes treatments for individual patients, considering their unique genetic makeup, environmental influences, and lifestyle choices to achieve better results and enhance care quality. Advances in genomic technologies, allowing for exact identification of genetic differences and personalized therapies, are boosting the need for personalized medicine. By facilitating targeted immune modulation, T cell-specific surface glycoprotein CD28 plays a role in personalized medicine, leading to more accurate and potent therapies. It improves therapeutic results through fostering optimal T cell activation and refining immune responses specific to each patient. For example, data from February 2024, provided by the US-based nonprofit Personalized Medicine Coalition (PMC), indicates that the U.S. Food and Drug Administration (FDA) sanctioned 26 novel personalized medicines in 2023, marking a rise from the 12 approved in 2022. Consequently, the heightened focus on personalized medicine is a key factor propelling the expansion of the T cell-specific surface glycoprotein CD28 market.

How Is The T Cell Specific Surface Glycoprotein CD28 Market Segmented Across Key Categories?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented –

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

Which Upcoming Trends Are Expected To Influence The T Cell Specific Surface Glycoprotein CD28 Market?

Leading entities within the T cell-specific surface glycoprotein CD28 market are concentrating on creating novel offerings, particularly combination immunotherapies, with the aim of improving T cell activation, bolstering anti-tumor effectiveness, and elevating patient treatment outcomes. These immunotherapies involve therapeutic strategies that merge several immune-centric methods to strengthen the body’s defensive capabilities against illness. An illustrative example is from February 2025, when Rondo Therapeutics Inc., a US-based biopharmaceutical firm, disclosed preclinical findings concerning RNDO 564, which is a new CD28 Nectin 4 costimulatory bispecific antibody developed for advanced bladder cancer. This antibody is designed to specifically activate CD28 present on T cells when it binds to tumor cells that express Nectin-4, thereby boosting T-cell-mediated destruction of tumors while simultaneously reducing unintended toxicity. The presented data showcased significant anti-tumor effectiveness in preclinical studies, providing a basis for its continued progression as a prospective treatment option for individuals suffering from metastatic urothelial carcinoma.

Who Are The Dominant Players Shaping The T Cell Specific Surface Glycoprotein CD28 Market Landscape?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Read the full t cell specific surface glycoprotein cd28 market report here:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

What Are The Top-Performing Regions Within The T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored T Cell Specific Surface Glycoprotein CD28 Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp

Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2026, By The Business Research Company

Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/monitor-global-market-report

Display Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/display-monitor-global-market-report

Holter Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the t cell specific surface glycoprotein cd28 market from 2026–2035 with trusted insights from The Business Research Company

How is the T Cell Specific Surface Glycoprotein CD28 Market size predicted to change over the forecast window of 2026–2035?

The t cell specific surface glycoprotein cd28 market size has demonstrated robust expansion in recent years. It is anticipated to increase from $1.62 billion in 2025 to $1.78 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.0%. This growth during the historic period can be attributed to the early identification of cd28 as a t-cell co-stimulatory receptor, an increase in immunology research, the growing prevalence of autoimmune diseases, rising initiatives in cancer research, and the limited availability of monoclonal antibody therapies.

The t cell specific surface glycoprotein cd28 market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.7%. Key drivers for this growth during the forecast period include the advancement of lulizumab pegol and new cd28 inhibitors, an increase in preclinical and clinical studies, the incorporation of cd28-targeted treatments into autoimmune and cancer therapies, increased investment in biopharmaceutical research, and progress in immunomodulation and monoclonal antibody engineering. Significant trends expected over the forecast period encompass a greater embrace of flow cytometry and ELISA technologies, an increase in immunology and cancer research applications, the ongoing development of new cd28 inhibitors and biobetters, broadened research into stem cell and autoimmune diseases, and the inclusion of lulizumab pegol in preclinical and clinical investigations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

Which Drivers Are Contributing To The Expansion Of The T Cell Specific Surface Glycoprotein CD28 Market?

The rising focus on personalized medicine is anticipated to fuel the expansion of the T cell-specific surface glycoprotein CD28 market in the future. Personalized medicine represents a medical strategy focused on customizing treatments for individual patients, taking into account their unique genetic makeup, environmental influences, and lifestyle, with the aim of maximizing therapeutic results and enhancing overall patient care. Demand for personalized medicine is on the rise, driven by progress in genomic technologies that facilitate accurate detection of genetic variations, leading to more customized treatments. T cell-specific surface glycoprotein CD28 contributes to personalized medicine by allowing for targeted immune system adjustments, thus making therapies more exact and potent. It improves therapeutic results through fostering optimal activation of T cells, thereby enhancing immune responses tailored to individual patients. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit, revealed that the U.S. Food and Drug Administration (FDA) granted approval to 26 new personalized medicines during 2023, marking an increase from the 12 approvals seen in 2022. Consequently, the increasing focus on personalized medicine is fueling the expansion of the T cell-specific surface glycoprotein CD28 market.

What Segment Classifications Make Up The T Cell Specific Surface Glycoprotein CD28 Market?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented –

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

What Trends Are Projected To Support The Growth Of The T Cell Specific Surface Glycoprotein CD28 Market?

Major companies operating in the T cell-specific surface glycoprotein CD28 market are focusing on developing innovative products, such as combination immunotherapies, to enhance T cell activation, anti-tumor efficacy, and patient treatment outcomes. Combination immunotherapies are treatments that combine multiple immune-based approaches to boost the body’s ability to fight disease. For instance, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, released preclinical data on RNDO 564, a novel CD28 Nectin 4 costimulatory bispecific antibody for advanced bladder cancer. This compound is engineered to selectively activate CD28 on T cells upon binding to Nectin-4-expressing tumor cells, enhancing T-cell-mediated tumor killing while minimizing off-target toxicity. The data demonstrated potent anti-tumor activity in preclinical models, supporting further development as a potential therapy for patients with metastatic urothelial carcinoma.

Which Key Market Players Are Investing In Expansion And Innovation Within The T Cell Specific Surface Glycoprotein CD28 Market?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

Which Regions Are Poised For Strategic Growth In The T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized T Cell Specific Surface Glycoprotein CD28 Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp

Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2026, By The Business Research Company

Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/monitor-global-market-report

Display Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/display-monitor-global-market-report

Holter Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the t cell specific surface glycoprotein cd28 market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present And Forecasted Size Of The T Cell Specific Surface Glycoprotein CD28 Market?

The T cell-specific surface glycoprotein CD28 market has experienced substantial expansion recently. Forecasts indicate a rise from $1.47 billion in 2024 to $1.62 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.1%. This historical growth is attributable to factors such as expanded research in immunotherapy, the escalating prevalence of cancer, an increase in autoimmune disease cases, a rise in clinical trials, and greater uptake of monoclonal antibodies.

The market for T cell-specific surface glycoprotein CD28 is projected to experience substantial expansion over the upcoming years. By 2029, this market is anticipated to reach a valuation of $2.35 billion, achieving a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period stems from several factors, including the escalating demand for personalized medicine, a heightened emphasis on T-cell-based therapeutic approaches, increased recognition of immuno-oncology, an expanding array of targeted therapies in development, augmented investments from pharmaceutical firms, and broader applications in the treatment of chronic diseases. Key trends defining this period involve significant progress in cell engineering technologies, sophisticated advancements in the development of bispecific antibodies, novel innovations within targeted immunotherapies, the incorporation of AI into drug discovery processes, and enhancements in biologics manufacturing.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

What Underlying Factors Are Supporting The T Cell Specific Surface Glycoprotein CD28 Market Growth?

The market for T cell-specific surface glycoprotein CD28 is expected to grow due to the increasing emphasis on personalized medicine moving forward. Personalized medicine is a medical approach that customizes treatments for individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and enhance care. The demand for personalized medicine is on the rise, driven by advancements in genomic technologies that enable precise identification of genetic variations and the creation of tailored treatments. T cell-specific surface glycoprotein CD28 aids personalized medicine by facilitating targeted immune modulation, which results in more precise and effective therapies. It improves treatment efficacy by promoting optimal T cell activation, thereby enhancing patient-specific immune responses. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, an increase from 12 approvals in 2022. Therefore, the expanding focus on personalized medicine is propelling the growth of the T cell-specific surface glycoprotein CD28 market.

How Does The T Cell Specific Surface Glycoprotein CD28 Market Differ By Segment?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

What New Opportunities Are Emerging From Trends In The T Cell Specific Surface Glycoprotein CD28 Market?

Major companies engaged in the T cell-specific surface glycoprotein CD28 market are directing their efforts towards creating innovative products, including combination immunotherapies, to improve T cell activation, anti-tumor efficacy, and patient treatment results. Combination immunotherapies are treatments that integrate multiple immune-based strategies to enhance the body’s capability to combat disease. For example, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, disclosed preclinical data concerning RNDO 564, an innovative CD28 Nectin 4 costimulatory bispecific antibody designed for advanced bladder cancer. It is specifically engineered to activate CD28 on T cells upon attachment to Nectin-4-expressing tumor cells, thereby augmenting T-cell-mediated tumor killing while reducing off-target toxicity. The data showcased strong anti-tumor activity in preclinical models, supporting its continued development as a potential therapy for patients suffering from metastatic urothelial carcinoma.

Who Are The Global Leaders Steering The T Cell Specific Surface Glycoprotein CD28 Market Forward?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

Which Region Is Likely To Register The Fastest Growth In The T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp

Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2025, By The Business Research Company

Monitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/monitor-global-market-report

Holter Monitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report

Steam And Air Conditioning Supply Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/steam-and-air-conditioning-supply-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The T Cell Specific Surface Glycoprotein CD28 Market Size During 2025–2029?

The market for T cell-specific surface glycoprotein CD28 has witnessed rapid expansion in recent years. It is anticipated to increase from $1.47 billion in 2024 to $1.62 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.1%. The historical development of this market can be attributed to factors like heightened research in immunotherapy, the escalating prevalence of cancer, an increase in autoimmune disease cases, a rise in clinical trials, and the growing adoption of monoclonal antibodies.

The T cell-specific surface glycoprotein CD28 market is anticipated to exhibit significant growth over the next few years, with its size projected to reach $2.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.8%. This expansion during the forecast period is propelled by factors such as an escalating demand for personalized medicine, an increasing focus on T-cell-based therapies, rising awareness surrounding immuno-oncology, an expanding pipeline of targeted therapies, growing investments from pharmaceutical companies, and broader applications in chronic diseases. Prominent trends observed for the forecast period include advancements in cell engineering technologies, sophisticated development of bispecific antibodies, innovations in targeted immunotherapies, the integration of AI within drug discovery, and improvements in the manufacturing of biologics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

Which Industry Drivers Are Expected To Accelerate The T Cell Specific Surface Glycoprotein CD28 Market From 2025 To 2029?

An increasing focus on personalized medicine is anticipated to drive the expansion of the T cell-specific surface glycoprotein CD28 market in the future. This medical strategy involves customizing treatments for individual patients, considering their genetic, environmental, and lifestyle elements to achieve better results and enhance care. Demand for personalized medicine is rising, propelled by progress in genomic technologies that facilitate accurate identification of genetic differences and allow for individualized therapeutic approaches. T cell-specific surface glycoprotein CD28 contributes to personalized medicine by allowing for targeted immune system adjustments, thus making treatments more accurate and potent. It improves therapeutic results through fostering optimal T cell activation, which in turn enhances immune responses tailored to specific patients. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit group, indicated that the U.S. Food and Drug Administration (FDA) cleared 26 new personalized medicines in 2023, a significant rise from the 12 approved in 2022. Consequently, the increasing focus on personalized medicine is fueling the expansion of the T cell-specific surface glycoprotein CD28 market.

How Is The T Cell Specific Surface Glycoprotein CD28 Market Segmented?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

Which Market Trends Are Creating New Opportunities In The T Cell Specific Surface Glycoprotein CD28 Industry?

Leading companies in the T cell-specific surface glycoprotein CD28 market are concentrating on developing innovative products, such as combination immunotherapies, to enhance T cell activation, improve anti-tumor efficacy, and better patient treatment outcomes. Combination immunotherapies are treatments that integrate multiple immune-based approaches to strengthen the body’s ability to combat disease. For instance, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, unveiled preclinical data on RNDO 564, a novel CD28 Nectin 4 costimulatory bispecific antibody intended for advanced bladder cancer. It is specifically engineered to selectively activate CD28 on T cells upon interaction with Nectin-4-expressing tumor cells, thereby boosting T-cell-mediated tumor killing while minimizing off-target toxicity. The data demonstrated potent anti-tumor activity in preclinical models, lending support for its further development as a potential therapy for patients with metastatic urothelial carcinoma.

Which Key Market Players Are Investing In Expansion And Innovation Of T Cell Specific Surface Glycoprotein CD28 Market?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The T Cell Specific Surface Glycoprotein CD28 Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp

Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2025, By The Business Research Company

Monitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/monitor-global-market-report

Display Monitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/display-monitor-global-market-report

Holter Monitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the T Cell Specific Surface Glycoprotein CD28 Sector?

The market size for the T cell-specific surface glycoprotein CD28 has witnessed swift expansion in the past few years. Projected growth will see the size increase from $1.47 billion in 2024 to $1.62 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.1%. Factors contributing to the growth in the historic period include escalating research in immunotherapy, growing cancer rates, increase in instances of autoimmune diseases, a surge in clinical trials, and more widespread use of monoclonal antibodies.

The market size for the T cell-specific surface glycoprotein CD28 is forecasted to experience considerable growth in the following years. It is projected to reach $2.35 billion by 2029 with a compound annual growth rate (CAGR) of 9.8%. This growth during the forecast period is credited to the surge in demand for personalized medicine, increased focus on T-cell-based therapies, heightened knowledge on immuno-oncology, a growing roster of targeted therapies, substantial investments by pharmaceutical corporations, and widened applications in chronic diseases. Key trends for the prediction period include advancements in cell engineering technologies, further development of bispecific antibodies, novel strategies in targeted immunotherapies, the implementation of AI in drug discovery, and progress in biologics production.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

What Forces Are Driving The Growth Of The T Cell Specific Surface Glycoprotein CD28 Market?

The expansion of the T cell-specific surface glycoprotein CD28 market is being spurred by the rising focus on personalized medicine. This medical approach concentrates on customizing treatments to individual patients by considering their genetic, environmental, and lifestyle factors to enhance results and healthcare quality. The need for such personalized care is growing, thanks to advances in genomic technologies. These tools allow for accurate pinpointing of genetic variations and the creation of treatments suited to each individual. T cell-specific surface glycoprotein CD28 bolsters personalized medicine by facilitating targeted immune modulation and making therapies more exact and potent. Such improvement in treatment outcomes is due to the promotion of ideal T cell activation, which strengthens patient-specific immune responses. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023. This was a significant increase from the 12 that were approved in 2022. Consequently, the escalating emphasis on personalized medicine is fueling the growth of the T cell-specific surface glycoprotein CD28 market.

How Is The T Cell Specific Surface Glycoprotein CD28 Industry Segmented Across Key Parameters?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

What Notable Trends Are Shaping The Direction Of The T Cell Specific Surface Glycoprotein CD28 Market?

Prominent entities functioning in the T cell-specific surface glycoprotein CD28 market are centering their efforts on the creation of novel solutions, such as combination immunotherapies. These therapies aim to amplify T cell activation, augment anti-cancer potency, and improve patient health outcomes. Combination immunotherapies merge a range of immune-based strategies to strengthen the body’s disease-fighting capabilities. For instance, Rondo Therapeutics Inc., a biopharmaceutical establishment based in the United States, disclosed preclinical data regarding RNDO 564 in February 2025. This innovative CD28 Nectin 4 costimulatory bispecific antibody, devised for evolved bladder cancer, is tailored to stimulate CD28 on T cells when they attach to Nectin-4-expressing cancer cells. This enhances T-cell-triggered cancer cell elimination while reducing unintended toxicity. Preliminary models exhibited strong anti-cancer activity from the data, bolstering further progress towards its potential application for patients diagnosed with metastatic urothelial carcinoma.

Which Companies Currently Dominate The Competitive Landscape In The T Cell Specific Surface Glycoprotein CD28 Industry?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

Which Geographic Regions Are Driving Demand In The T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model